Table 1 Patient demographic and clinical characteristics
Characteristic | Sunitinib (N = 64) |
|---|---|
Median (range) age, years | 52 (36–70) |
ECOG performance status, n (%) | Â |
  0 | 24 (38) |
  1 | 40 (63) |
Histologic type, n (%) | Â |
  Ductal | 54 (84) |
  Inflammatory | 4 (6) |
  Other | 6 (9) |
Receptor status, n (%) | Â |
  ER-positive | 37 (58) |
  PgR-positive | 26 (41) |
  HER2-positive | 12 (19) |
  Triple-negative | 20 (31) |
Metastatic sites, n (%) | Â |
  Lymph nodes | 41 (64) |
  Liver | 38 (59) |
  Lung | 31 (48) |
  Bone | 25 (39) |
  Pleural effusion | 17 (27) |
  Local recurrence | 16 (25) |
  Skin | 14 (22) |
  Primary tumor | 4 (6) |
Prior systemic therapy,* n (%) | 64 (100) |
  Anthracycline + taxane + other | 60 (94) |
  Anthracycline + taxane | 1 (2) |
  Anthracycline + other | 2 (3) |
  Other | 1 (2) |